Skip to main content

First Circuit Joins Debate on Kickback Causation in False Claims Act Cases

Client memorandum | March 4, 2025

Authors: Alexander B. Ginsberg, Robin A. Henry, Ilan T. Graff, Jason S. Kanterman, Le G. Ho

On February 18, 2025, the United States Court of Appeals for the First Circuit issued its decision in United States v. Regeneron Pharms., Inc., No. 23-2086, 2025 WL 520466 (1st Cir. Feb. 18, 2025), a closely watched False Claims Act (“FCA”) case with significant implications for healthcare providers.  The First Circuit joined the growing majority of federal appellate courts in holding that plaintiffs must demonstrate but-for causation to succeed with kickback-related FCA claims arising out of a 2010 amendment to the Anti-Kickback Statute (“AKS”).  The court’s decision comes as the Department of Justice (“DOJ”) has underscored its intent “to continue to aggressively enforce the [FCA].”[1]

The case began in 2020, when the DOJ brought suit in the United States District Court for the District of Massachusetts, alleging that the Defendant, a pharmaceutical company, improperly incentivized doctors and patients to prefer its drug over less-expensive alternatives by subsidizing the associated co-pays and deductibles.  The Government alleged that this conduct violated both the FCA, 31 U.S.C. § 3729 et seq.—which prohibits the submission of false claims for payment to federal agencies—and the AKS, 42 U.S.C. § 1320a-7b, which makes it illegal to offer inducements to businesses that are paid by federal healthcare programs.  The Government specifically relied on a 2010 amendment to the AKS, which provides in relevant part that a claim “resulting from a violation of [the AKS] constitutes a false or fraudulent claim for purposes of [the FCA].”  See 42 U.S.C. § 1320a-7b(g) (the “2010 Amendment”).

In September 2023, the district court decided the parties’ respective motions for summary judgment, largely denying both.  The district court determined that the “resulting from” language of the 2010 Amendment requires the Government (or an FCA qui tam relator) to demonstrate that an AKS violation was a but-for cause of an alleged false claim before FCA liability can attach to a defendant’s conduct.  In other words, the district court held that an AKS violation does not result in per se FCA liability—even if the AKS violation partially influences the prescription.  Instead, FCA liability attaches only when a plaintiff establishes that the kickbacks at issue were the but-for cause of a healthcare provider’s choice to select a different treatment than it otherwise would have selected.  Acknowledging a growing circuit split on this issue (and even disagreement within the District of Massachusetts itself), the district court certified its decision for appeal.

On appeal, the First Circuit agreed with the district court that, when a plaintiff alleges a false claim resulted from a violation of the AKS, the plaintiff must demonstrate that the AKS violation was the but-for cause of the claim.  The First Circuit joins the Sixth[2] and Eighth[3] Circuits in reaching this conclusion, contributing to a developing consensus against the more permissive standard applied by the Third Circuit in United States ex rel. Greenfield v. Medco Health Sols., Inc., 880 F.3d 89 (3d Cir. 2018), which held that a patient need only be “exposed to an illegal recommendation or referral” to render “a claim for reimbursement pertaining to that patient” false for purposes of the FCA.

Thus, the First Circuit’s decision reflects a growing agreement among federal appellate courts that FCA plaintiffs must demonstrate but-for causation when pursuing FCA claims arising under the 2010 Amendment.  Because the FCA provides for national jurisdiction and allows claims to be brought in any district in which any defendant resides or transacts business, it is reasonable to expect plaintiffs with AKS-based FCA claims arising under the 2010 Amendment will seek recourse in the Third Circuit.  Companies facing such claims should consider jurisdictional and venue-based defenses, as such defenses may prove outcome determinative. 


[1] Daniel Wilson, DOJ Official Flags ‘Aggressive’ FCA Approach Under Trump, Law360 (Feb. 20, 2025, 5:25 PM), https://www.law360.com/articles/2300751/doj-official-flags-aggressive-fca-approach-under-trump.

[2] United States ex rel. Martin v. Hathaway, 63 F.4th 1043 (6th Cir. 2023).

[3] United States ex rel. Cairns v. D.S. Med. LLC, 42 F.4th 828 (8th Cir. 2022).


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.